JP2014511686A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014511686A5 JP2014511686A5 JP2014502867A JP2014502867A JP2014511686A5 JP 2014511686 A5 JP2014511686 A5 JP 2014511686A5 JP 2014502867 A JP2014502867 A JP 2014502867A JP 2014502867 A JP2014502867 A JP 2014502867A JP 2014511686 A5 JP2014511686 A5 JP 2014511686A5
- Authority
- JP
- Japan
- Prior art keywords
- wing
- compound according
- nucleoside
- modified
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 27
- 239000002777 nucleoside Substances 0.000 claims 27
- 108091034117 Oligonucleotide Proteins 0.000 claims 12
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 10
- 125000003835 nucleoside group Chemical group 0.000 claims 10
- -1 bicyclic nucleoside Chemical class 0.000 claims 6
- 230000000295 complement effect Effects 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000003463 hyperproliferative effect Effects 0.000 claims 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940104302 cytosine Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161471045P | 2011-04-01 | 2011-04-01 | |
| US201161471035P | 2011-04-01 | 2011-04-01 | |
| US201161471015P | 2011-04-01 | 2011-04-01 | |
| US201161471001P | 2011-04-01 | 2011-04-01 | |
| US61/471,001 | 2011-04-01 | ||
| US61/471,045 | 2011-04-01 | ||
| US61/471,035 | 2011-04-01 | ||
| US61/471,015 | 2011-04-01 | ||
| US201161558308P | 2011-11-10 | 2011-11-10 | |
| US201161558316P | 2011-11-10 | 2011-11-10 | |
| US61/558,308 | 2011-11-10 | ||
| US61/558,316 | 2011-11-10 | ||
| PCT/US2012/031642 WO2012135736A2 (en) | 2011-04-01 | 2012-03-30 | Modulation of signal transducer and activator of transcription 3 (stat3) expression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014511686A JP2014511686A (ja) | 2014-05-19 |
| JP2014511686A5 true JP2014511686A5 (enExample) | 2015-04-09 |
| JP5943993B2 JP5943993B2 (ja) | 2016-07-05 |
Family
ID=46932413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014502867A Active JP5943993B2 (ja) | 2011-04-01 | 2012-03-30 | 転写のシグナル伝達及び活性化因子３（ｓｔａｔ３）発現の調節 |
Country Status (35)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012135736A2 (en) | 2011-04-01 | 2012-10-04 | Isis Pharmaceuticals, Inc. | Modulation of signal transducer and activator of transcription 3 (stat3) expression |
| ES2742284T3 (es) * | 2012-03-28 | 2020-02-13 | Somalogic Inc | Aptámeros contra PDGF y VEGF y su utilización en el tratamiento de afecciones mediadas por PDGF y VEGF |
| WO2014062736A1 (en) | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Methods for monitoring c9orf72 expression |
| US10443052B2 (en) * | 2012-10-15 | 2019-10-15 | Ionis Pharmaceuticals, Inc. | Compositions for modulating C9ORF72 expression |
| CN104755621A (zh) * | 2012-10-31 | 2015-07-01 | 埃西斯药品公司 | 癌症治疗 |
| PE20152002A1 (es) | 2013-05-01 | 2016-01-21 | Isis Pharmaceuticals Inc | Composiciones y metodos para modular la expresion de ttr y vhb |
| WO2015002971A2 (en) * | 2013-07-02 | 2015-01-08 | Isis Pharmaceuticals, Inc. | Modulators of growth hormone receptor |
| CA3221709A1 (en) | 2013-09-09 | 2015-03-12 | Somalogic Operating Co., Inc. | Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders |
| MX2016004651A (es) | 2013-10-11 | 2016-08-05 | Ionis Pharmaceuticals Inc | Composiciones para modular la expresion de c9orf72. |
| ES2844593T3 (es) | 2014-05-01 | 2021-07-22 | Ionis Pharmaceuticals Inc | Composiciones y procedimientos para modular la expresión de la angiopoyetina de tipo 3 |
| ES2812099T3 (es) | 2014-05-01 | 2021-03-16 | Ionis Pharmaceuticals Inc | Composiciones y métodos para modular la expresión del receptor de la hormona del crecimiento |
| RS59182B1 (sr) | 2014-05-01 | 2019-10-31 | Ionis Pharmaceuticals Inc | Kompozicije i postupci za modulaciju ekspresije faktora b komplementa |
| WO2015179693A1 (en) | 2014-05-22 | 2015-11-26 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| WO2016034611A1 (en) * | 2014-09-02 | 2016-03-10 | Max-Delbrück-Centrum für Molekulare Medizin | Antisense oligonucleotides targeting 3'utr region of a20 |
| CN115920007A (zh) | 2014-10-24 | 2023-04-07 | 阿斯利康(瑞典)有限公司 | 组合 |
| EP3722424A1 (en) | 2015-04-16 | 2020-10-14 | Ionis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
| JP7073109B2 (ja) | 2015-07-02 | 2022-05-23 | シティ・オブ・ホープ | ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法 |
| MY192997A (en) | 2015-07-10 | 2022-09-20 | Ionis Pharmaceuticals Inc | Modulators of diacyglycerol acyltransferase 2 (dgat2) |
| SG11201802718PA (en) | 2015-10-14 | 2018-05-30 | Bio Path Holdings Inc | P-ethoxy nucleic acids for liposomal formulation |
| WO2017079291A1 (en) | 2015-11-02 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating c90rf72 |
| EP3372233B1 (en) | 2015-11-06 | 2021-07-07 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| KR20250078597A (ko) | 2015-11-06 | 2025-06-02 | 아이오니스 파마수티컬즈, 인코포레이티드 | 아포리포프로테인 (a) 발현 조정 |
| US11390867B2 (en) | 2016-04-29 | 2022-07-19 | Nanyang Technological University | G-quadruplex-containing antisense oligonucleotides |
| CN105985961B (zh) * | 2016-07-22 | 2019-01-29 | 广西师范大学 | 抑制EGFR基因表达的siRNA及其应用 |
| SG10202008771WA (en) | 2016-09-16 | 2020-10-29 | Bio Path Holdings Inc | Combination therapy with liposomal antisense oligonucleotides |
| KR20190065341A (ko) | 2016-10-06 | 2019-06-11 | 아이오니스 파마수티컬즈, 인코포레이티드 | 올리고머 화합물들의 접합 방법 |
| WO2018102397A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| EP3612160A4 (en) | 2017-04-19 | 2021-01-20 | Bio-Path Holdings, Inc. | P-ETHOXY NUCLEIC ACIDS TO INHIBIT BCL2 |
| SG11201909336VA (en) * | 2017-04-19 | 2019-11-28 | Bio Path Holdings Inc | P-ethoxy nucleic acids for stat3 inhibition |
| GB2574793B (en) * | 2018-05-01 | 2022-09-28 | Flexenable Ltd | Organic liquid crystal display device with one or more oxygen permeable films |
| TWI869213B (zh) * | 2018-09-19 | 2025-01-01 | 美商Ionis製藥公司 | Pnpla3表現之調節劑 |
| CA3147366A1 (en) * | 2019-08-14 | 2021-02-18 | Adam T. BOUTIN | Extracellular vesicles with stat3-antisense oligonucleotides |
| CN119746083A (zh) | 2019-09-30 | 2025-04-04 | 阿斯利康(瑞典)有限公司 | 用于癌症的组合治疗 |
| WO2021097437A1 (en) * | 2019-11-14 | 2021-05-20 | The Board Of Regents Of The University Of Oklahoma | Oligonucleotide interference treatments of prostate cancer |
| JP7674354B2 (ja) * | 2019-12-05 | 2025-05-09 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 肝線維症および線維症に関連する他の疾患に対するエキソソームベースの療法 |
| AU2021212949A1 (en) * | 2020-01-31 | 2022-09-01 | Nissan Chemical Corporation | Antisense oligonucleotide of ATN1 |
| CN114908094B (zh) * | 2022-05-31 | 2024-03-12 | 中山大学 | 一类反义寡核苷酸分子及其在制备治疗恶性肿瘤药物中的应用 |
| WO2024003241A1 (en) | 2022-06-30 | 2024-01-04 | Astrazeneca Ab | Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
| US2699508A (en) | 1951-12-21 | 1955-01-11 | Selectronics Inc | Method of mounting and construction of mounting for low frequency piezoelectric crystals |
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| AU2580892A (en) | 1991-09-05 | 1993-04-05 | Isis Pharmaceuticals, Inc. | Determination of oligonucleotides for therapeutics, diagnostics and research reagents |
| EP0673559A1 (en) | 1992-12-14 | 1995-09-27 | Honeywell Inc. | Motor system with individually controlled redundant windings |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| EP0676469A3 (en) | 1994-04-04 | 1998-03-25 | Tadamitsu Kishimoto | Transcription Factor APRF |
| JPH10510981A (ja) | 1994-05-16 | 1998-10-27 | ブリガム アンド ウィメンズ ホスピタル | ヌクレオチド配列を特性決定するための方法、装置及び組成物 |
| EP0717110A1 (en) | 1994-11-22 | 1996-06-19 | Association Francaise Contre Les Myopathies | LGMD gene |
| US5877021A (en) | 1995-07-07 | 1999-03-02 | Ribozyme Pharmaceuticals, Inc. | B7-1 targeted ribozymes |
| US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
| US6514725B1 (en) | 1997-01-10 | 2003-02-04 | Tadamitsu Kishimoto | STAT function-regulatory protein |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| DE69829760T3 (de) | 1997-09-12 | 2016-04-14 | Exiqon A/S | Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga |
| US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
| US6159694A (en) | 1999-04-08 | 2000-12-12 | Isis Pharmaceuticals Inc. | Antisense modulation of stat3 expression |
| AU776362B2 (en) | 1999-05-04 | 2004-09-09 | Roche Innovation Center Copenhagen A/S | L-ribo-LNA analogues |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| JP2003504048A (ja) | 1999-07-09 | 2003-02-04 | ユニベルシテ ドゥ リエージュ | 低温活性ベータ・ガラクトシダーゼ、その製法、及びその使用 |
| US6248586B1 (en) | 1999-12-17 | 2001-06-19 | Isis Pharmaceuticals, Inc. | Antisense modulation of PKA catalytic subunit C-alpha expression |
| WO2002092616A1 (en) | 2001-05-11 | 2002-11-21 | Orasense, Ltd. | Antisense permeation enhancers |
| US20050196781A1 (en) | 2001-05-18 | 2005-09-08 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of STAT3 gene expression using short interfering nucleic acid (siNA) |
| CA2452458A1 (en) | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| WO2003008578A2 (en) | 2001-07-20 | 2003-01-30 | Board Of Trustees Of The University Of Illinois | Reagents and methods for identifying gene targets for treating cancer |
| US7259150B2 (en) * | 2001-08-07 | 2007-08-21 | Isis Pharmaceuticals, Inc. | Modulation of apolipoprotein (a) expression |
| AU2003295387A1 (en) | 2002-11-05 | 2004-06-03 | Isis Parmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
| EP1562971B1 (en) | 2002-11-05 | 2014-02-12 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| US8090542B2 (en) | 2002-11-14 | 2012-01-03 | Dharmacon Inc. | Functional and hyperfunctional siRNA |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| DK1661905T3 (da) | 2003-08-28 | 2012-07-23 | Takeshi Imanishi | Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype |
| AU2004274021B2 (en) | 2003-09-18 | 2009-08-13 | Isis Pharmaceuticals, Inc. | 4'-thionucleosides and oligomeric compounds |
| CN100357436C (zh) * | 2005-07-01 | 2007-12-26 | 中国人民解放军第三军医大学 | 抑制Stat3基因表达的siRNA及其制备方法 |
| CN1733916A (zh) * | 2005-07-01 | 2006-02-15 | 中国人民解放军第三军医大学 | 抑制Stat3基因表达的siRNA及其制备方法 |
| CA2640171C (en) | 2006-01-27 | 2014-10-28 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
| JP5441688B2 (ja) | 2006-05-11 | 2014-03-12 | アイシス ファーマシューティカルズ， インコーポレーテッド | ５’修飾二環式核酸類似体 |
| WO2008101157A1 (en) | 2007-02-15 | 2008-08-21 | Isis Pharmaceuticals, Inc. | 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom |
| US20100105134A1 (en) | 2007-03-02 | 2010-04-29 | Mdrna, Inc. | Nucleic acid compounds for inhibiting gene expression and uses thereof |
| WO2008109494A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting stat3 gene expression and uses thereof |
| EP2170917B1 (en) | 2007-05-30 | 2012-06-27 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| ES2386492T3 (es) | 2007-06-08 | 2012-08-21 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos carbocíclicos |
| CN101796062B (zh) | 2007-07-05 | 2014-07-30 | Isis制药公司 | 6-双取代双环核酸类似物 |
| WO2009039189A2 (en) * | 2007-09-17 | 2009-03-26 | Intradigm Corporation | Compositions comprising stat3 sirna and methods of use thereof |
| AT507215B1 (de) | 2009-01-14 | 2010-03-15 | Boehler Edelstahl Gmbh & Co Kg | Verschleissbeständiger werkstoff |
| WO2012135736A2 (en) | 2011-04-01 | 2012-10-04 | Isis Pharmaceuticals, Inc. | Modulation of signal transducer and activator of transcription 3 (stat3) expression |
| US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
| CN104755621A (zh) | 2012-10-31 | 2015-07-01 | 埃西斯药品公司 | 癌症治疗 |
| US9778708B1 (en) | 2016-07-18 | 2017-10-03 | Lenovo Enterprise Solutions (Singapore) Pte. Ltd. | Dual sided latching retainer for computer modules |
-
2012
- 2012-03-30 WO PCT/US2012/031642 patent/WO2012135736A2/en not_active Ceased
- 2012-03-30 PT PT12763390T patent/PT2697243T/pt unknown
- 2012-03-30 AU AU2012236206A patent/AU2012236206C1/en active Active
- 2012-03-30 EP EP18201757.4A patent/EP3466960A3/en not_active Withdrawn
- 2012-03-30 RS RS20190022A patent/RS58489B1/sr unknown
- 2012-03-30 HR HRP20182169TT patent/HRP20182169T1/hr unknown
- 2012-03-30 LT LTEP12763390.7T patent/LT2697243T/lt unknown
- 2012-03-30 EA EA201792185A patent/EA201792185A3/ru unknown
- 2012-03-30 ES ES12763390T patent/ES2709495T3/es active Active
- 2012-03-30 US US13/436,558 patent/US8816056B2/en active Active
- 2012-03-30 ME MEP-2019-20A patent/ME03317B/me unknown
- 2012-03-30 EA EA201391329A patent/EA029317B1/ru not_active IP Right Cessation
- 2012-03-30 BR BR112013024768-1A patent/BR112013024768B1/pt active IP Right Grant
- 2012-03-30 SI SI201231497T patent/SI2697243T1/sl unknown
- 2012-03-30 MX MX2013011423A patent/MX340086B/es active IP Right Grant
- 2012-03-30 JP JP2014502867A patent/JP5943993B2/ja active Active
- 2012-03-30 PE PE2013002156A patent/PE20142463A1/es active IP Right Grant
- 2012-03-30 CN CN201611204855.1A patent/CN107012144A/zh active Pending
- 2012-03-30 SG SG2013069935A patent/SG193504A1/en unknown
- 2012-03-30 CA CA2831915A patent/CA2831915C/en active Active
- 2012-03-30 HU HUE12763390A patent/HUE042173T2/hu unknown
- 2012-03-30 DK DK12763390.7T patent/DK2697243T3/en active
- 2012-03-30 SM SM20190060T patent/SMT201900060T1/it unknown
- 2012-03-30 EP EP12763390.7A patent/EP2697243B1/en active Active
- 2012-03-30 PE PE2018001314A patent/PE20181518A1/es unknown
- 2012-03-30 KR KR1020197021858A patent/KR20190092590A/ko not_active Abandoned
- 2012-03-30 MY MYPI2013701834A patent/MY163004A/en unknown
- 2012-03-30 PH PH1/2013/502049A patent/PH12013502049A1/en unknown
- 2012-03-30 PL PL12763390T patent/PL2697243T3/pl unknown
- 2012-03-30 CN CN201280026065.2A patent/CN103562215B/zh active Active
- 2012-03-30 KR KR1020137028986A patent/KR102050469B1/ko active Active
-
2013
- 2013-09-26 CO CO13229252A patent/CO6821885A2/es unknown
- 2013-09-26 CL CL2013002773A patent/CL2013002773A1/es unknown
- 2013-09-27 DO DO2013000216A patent/DOP2013000216A/es unknown
- 2013-09-27 GT GT201300232A patent/GT201300232A/es unknown
- 2013-09-29 IL IL228569A patent/IL228569A/en active IP Right Grant
- 2013-09-30 EC ECSP13012909 patent/ECSP13012909A/es unknown
- 2013-09-30 NI NI201300101A patent/NI201300101A/es unknown
- 2013-10-31 ZA ZA2013/08153A patent/ZA201308153B/en unknown
-
2014
- 2014-07-23 US US14/338,880 patent/US9359608B2/en active Active
-
2016
- 2016-05-09 US US15/149,642 patent/US10479993B2/en active Active
-
2017
- 2017-11-22 IL IL255858A patent/IL255858A/en unknown
-
2019
- 2019-01-18 CY CY20191100068T patent/CY1121460T1/el unknown
- 2019-10-08 US US16/595,924 patent/US20200385716A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014511686A5 (enExample) | ||
| JP2015501155A5 (enExample) | ||
| JP2016116520A5 (enExample) | ||
| JP2014530004A5 (enExample) | ||
| JP2016501513A5 (enExample) | ||
| JP2012505660A5 (enExample) | ||
| JP2015507625A5 (enExample) | ||
| JP2012050438A5 (enExample) | ||
| JP2013516190A5 (enExample) | ||
| JP2019088329A5 (enExample) | ||
| JP2017510271A5 (enExample) | ||
| JP2015536132A5 (enExample) | ||
| JP2020022483A5 (enExample) | ||
| JP2014521310A5 (enExample) | ||
| JP2016513976A5 (enExample) | ||
| JP2017505623A5 (enExample) | ||
| JP2014513954A5 (enExample) | ||
| TWI762732B (zh) | 用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子 | |
| JP2017513469A5 (enExample) | ||
| RU2017120536A (ru) | Способы и композиции для модулирования экспрессии аполипопротеина (а) | |
| JP2013226147A5 (enExample) | ||
| JP2016171800A5 (enExample) | ||
| JP2018126141A5 (enExample) | ||
| JP2013516489A5 (enExample) | ||
| JP2016531593A5 (enExample) |